Abstract:Post-translational modification by ubiquitin is crucial for protein turnover. Deubiquitinases (DUBs) remove ubiquitin chains from target proteins to prevent their degradation by the proteasome, thus acting as gatekeepers of protein homeostasis alongside the ubiquitin-proteasome system (UPS). Tumor cells exhibit remarkable plasticity, enabling them to adapt to anticancer treatments and the conditions of the tumor microenvironment, including mechanical cues from the extracellular matrix (ECM). However, the role of DUBs in mechanotransduction remains unexplored. To identify DUBs involved in cancer cell mechanosignaling, we used melanoma cells grown on collagen matrices with varying stiffnesses and an activity-based ubiquitin probe to profile DUB activities. Our approach, combined with quantitative proteomics, revealed that ubiquitin-specific protease 9X (USP9X) is sensitive to ECM stiffness through discoidin domain receptors (DDR)/actomyosin signaling pathway. In silico analysis further indicated that the mechanosensor YAP is part of the USP9X interactome, and USP9X expression correlates with the YAP transcriptional signature in melanoma. We hypothesized that mechanical signals regulate YAP levels through USP9X DUB activity. Consistently, low collagen stiffness reduced YAP expression, and siRNA-mediated depletion or pharmacological inhibition of USP9X decreased YAP protein expression in tumor cells. Conversely, knockdown of the ubiquitin E3 ligase βTrCP increased YAP protein levels. Affinity purification of polyubiquitinated proteins using Tandem Ubiquitin Binding Entities (TUBEs) showed that combined USP9X and proteasome inhibition increased YAP poly-ubiquitination, revealing that USP9X deubiquitinates YAP to prevent its proteasomal degradation. Targeting USP9X impaired stiffness-mediated responses, including YAP nuclear translocation and transcriptional activity, cell migration and invasion, and drug resistance. An experimental metastasis assay showed that stable knockdown of USP9X impaired melanoma cell lung colonization. Finally, targeting USP9X in a syngeneic BRAF-mutant melanoma model counteracted targeted therapy-induced ECM remodeling, enhanced treatment efficacy, and delayed tumor relapse. Our findings reveal a novel role of USP9X in cancer cell mechanobiology and drug resistance through stiffness-dependent stabilization of the oncoprotein YAP, proposing USP9X as a targetable "mechano-DUB" in cancer.

Deubiquitylase USP9X Suppresses Tumorigenesis by Stabilizing Large Tumor Suppressor Kinase 2 (LATS2) in the Hippo Pathway.

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP

USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilization

Deubiquitinase USP9X Deubiquitinates Β-Catenin and Promotes High Grade Glioma Cell Growth

USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ

USP12 facilitates gastric cancer progression via stabilizing YAP

USP20 mediates bladder cancer progression via altering the activity of Hippo-YAP axis through directly stabilizing YAP1 protein

Cell type-dependent function of LATS1/2 in cancer cell growth

Ubiquitin-specific Protease 11 (USP11) Functions As a Tumor Suppressor Through Deubiquitinating and Stabilizing VGLL4 Protein.

Usp7 regulates Hippo pathway through deubiquitinating the transcriptional coactivator Yorkie

DUB1 Suppresses Hippo Signaling Via Modulating TAZ Protein in Gastric Cancer

USP9X destabilizes pVHL and promotes cell proliferation.

USP9X-mediated Deubiquitination of B-cell CLL/lymphoma 9 Potentiates Wnt Signaling and Promotes Breast Carcinogenesis

The Deubiquitinase USP10 Mediates Crosstalk Between the LKB1/AMPK Axis and Wnt/β-catenin Signaling in Cancer.

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants

Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1

USP10 Suppresses Tumor Progression by Inhibiting Mtor Activation in Hepatocellular Carcinoma.